Author: admin

Chronic Hand Eczema Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Basilea Pharma, Stiefel Labs, LEO Pharma, Asana Biosciences, Incyte

The Key Chronic Hand Eczema Companies in the market include – Basilea Pharmaceutica/ Stiefel Laboratories, LEO Pharma, Asana Biosciences and Incyte Corporation, and others.

 

The Chronic Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Hand Eczema pipeline products will significantly revolutionize the Chronic Hand Eczema market dynamics.

 

DelveInsight’s “Chronic Hand Eczema Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Hand Eczema, historical and forecasted epidemiology as well as the Chronic Hand Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Chronic Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Hand Eczema Market Forecast

 

Some of the key facts of the Chronic Hand Eczema Market Report:

  • The Chronic Hand Eczema market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In February 2025, LEO Pharma A/S, a global leader in medical dermatology, has announced positive top-line results for the primary endpoint from the double-blind phase of its Phase 3 DELTA China trial. The study evaluated Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of moderate to severe Chronic Hand Eczema (CHE) in Chinese adolescents and adults (12 years and older) who do not respond adequately to or are unsuitable for topical corticosteroids.

  • In September 2024, LEO Pharma Inc. garnered attention with two significant announcements. Firstly, the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%), designed for adults experiencing moderate to severe Chronic Hand Eczema (CHE). This development is particularly important for patients who have not had favorable responses to topical corticosteroids or for those for whom such treatments are inappropriate.

  • In September 2024, LEO Pharma A/S announced that the European Commission (EC) has granted marketing authorization for Anzupgo® (delgocitinib) cream. This approval provides a new treatment option for adult patients with moderate to severe Chronic Hand Eczema (CHE) in Europe, particularly where conventional corticosteroid therapies have been ineffective. These two announcements highlight LEO Pharma’s continued leadership in medical dermatology and represent a significant advancement in enhancing care for individuals suffering from chronic hand eczema.

  • In 2023, the market size for chronic hand eczema in the US was approximately USD 431 million.

  • In 2023, Germany had the largest market size among the EU4 and the UK, at approximately USD 71 million, followed by France at nearly USD 46 million and the UK at around USD 45 million.

  • In 2023, Japan’s chronic hand eczema market size was approximately USD 93 million of the total market share.

  • According to DelveInsight’s analysis, the total prevalent cases of chronic hand eczema in the 7MM were about 4 million in 2023, with nearly 2 million of those cases occurring in the US.

  • Within the EU4 and the UK, Germany had the highest number of prevalent chronic hand eczema cases, with nearly 493,000 cases, followed by France and the UK with approximately 321,000 and 317,000 cases, respectively.

  • In the UK in 2023, there were approximately 52,000 cases of chronic hand eczema in the 20-29 age group, 98,000 cases in the 30-49 age group, 29,000 cases in the 50-69 age group, and 26,000 cases in the 70 and above age group.

  • In 2023, Japan accounted for nearly 15% of all chronic hand eczema cases worldwide. Among the various subtypes, irritant contact eczema had the highest prevalence at around 27%, while fingertip eczema was the least common, making up approximately 4% of the cases.

  • Key Chronic Hand Eczema Companies: Basilea Pharmaceutica/ Stiefel Laboratories, LEO Pharma, Asana Biosciences and Incyte Corporation, and others

  • Key Chronic Hand Eczema Therapies: TOCTINO (alitretinoin), Delgocitinib, Ruxolitinib, ASN002, and others

  • The Chronic Hand Eczema epidemiology based on gender analyzed that Chronic Hand Eczema is more common in males, than females

 

Chronic Hand Eczema Overview

Hand eczema are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder affecting the hands. It is not a uniform or homogeneous disease and varies by differences in etiology, morphology, and severity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance of contact with potentially damaging allergens and/or irritants.

Chronic Hand Eczema has been defined as either a long-lasting, relapsing course of HE or HE unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months or the recurrence of symptoms two or more times within a year despite treatment.

 

Get a Free sample for the Chronic Hand Eczema Market Report:

https://www.delveinsight.com/report-store/chronic-hand-eczema-market

 

Chronic Hand Eczema Epidemiology Segmentation:

The Chronic Hand Eczema market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Chronic Hand Eczema

  • Prevalent Cases of Chronic Hand Eczema by severity

  • Gender-specific Prevalence of Chronic Hand Eczema

  • Diagnosed Cases of Episodic and Chronic Chronic Hand Eczema

 

Download the report to understand which factors are driving Chronic Hand Eczema epidemiology trends @ Chronic Hand Eczema Epidemiological Insights

 

Chronic Hand Eczema Market

The dynamics of the Chronic Hand Eczema market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

 

Chronic Hand Eczema Therapies and Key Companies

  • TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories

  • Delgocitinib: LEO Pharma/Japan Tobacco

  • ARQ-252: Arcutis Biotherapeutics

  • ASN002: Asana BioScience

  • Ruxolitinib: Incyte Corporation

 

To know more about Chronic Hand Eczema treatment, visit @ Chronic Hand Eczema Medications

 

Chronic Hand Eczema Market Drivers

  • Government Initiatives

  • Growth in Research and Development

  • Increase in the number of patients

 

Chronic Hand Eczema Market Barriers

  • Lack of Approved Chronic Hand Eczema therapies

  • Lack of Clinical Trial studies

 

Scope of the Chronic Hand Eczema Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Chronic Hand Eczema Companies: Basilea Pharmaceutica/ Stiefel Laboratories, LEO Pharma, Incyte Corporation, Asana BioSciences, and others

  • Key Chronic Hand Eczema Therapies: TOCTINO (alitretinoin), Delgocitinib, Ruxolitinib, ASN002, and others

  • Chronic Hand Eczema Therapeutic Assessment: Chronic Hand Eczema current marketed and Chronic Hand Eczema emerging therapies

  • Chronic Hand Eczema Market Dynamics: Chronic Hand Eczema market drivers and Chronic Hand Eczema market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Chronic Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Chronic Hand Eczema Market Access and Reimbursement

 

Discover more about therapies set to grab major Chronic Hand Eczema market share @ Chronic Hand Eczema Treatment Landscape

 

Table of Contents

1. Chronic Hand Eczema Market Report Introduction

2. Executive Summary for Chronic Hand Eczema

3. SWOT analysis of Chronic Hand Eczema

4. Chronic Hand Eczema Patient Share (%) Overview at a Glance

5. Chronic Hand Eczema Market Overview at a Glance

6. Chronic Hand Eczema Disease Background and Overview

7. Chronic Hand Eczema Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Hand Eczema

9. Chronic Hand Eczema Current Treatment and Medical Practices

10. Chronic Hand Eczema Unmet Needs

11. Chronic Hand Eczema Emerging Therapies

12. Chronic Hand Eczema Market Outlook

13. Country-Wise Chronic Hand Eczema Market Analysis (2020–2034)

14. Chronic Hand Eczema Market Access and Reimbursement of Therapies

15. Chronic Hand Eczema Market Drivers

16. Chronic Hand Eczema Market Barriers

17. Chronic Hand Eczema Appendix

18. Chronic Hand Eczema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Hand Eczema Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Basilea Pharma, Stiefel Labs, LEO Pharma, Asana Biosciences, Incyte

Ulcerative Colitis Market Set for Robust Growth Across the 7MM from USD 8.4 Billion in 2023 | DelveInsight

Key Ulcerative Colitis companies in the market include – Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck and Mesoblast, among others.

The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions by companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck and Mesoblast, among others.

 

DelveInsight’s “Ulcerative Colitis Market Insight, Epidemiology And Market Forecast – 2034“ report delivers comprehensive insights into the ulcerative colitis market dynamics, epidemiological trends, and treatment landscape across the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The ulcerative colitis market size in the 7MM was USD 8.4 billion in 2023, with the United States accounting for the largest share at USD 5.9 billion. This market is poised for significant growth during the forecast period (2024-2034), driven by improved drug uptake, increased disease awareness, and a robust pipeline of innovative therapies.

 

Download the Ulcerative Colitis market report to understand which factors are driving the Ulcerative Colitis therapeutic market @ Ulcerative Colitis Market Trends

 

The report also provides a detailed epidemiological analysis and forecasts up to 2034, segmented by Total Diagnosed Prevalent Cases of Ulcerative Colitis, Age-specific Cases of Ulcerative Colitis, Severity-specific Cases of Ulcerative Colitis, and Total Treated Patients of Ulcerative Colitis.

 

According to the latest epidemiological analysis, the total diagnosed prevalent cases of ulcerative colitis in the 7MM comprised approximately 3 Million in 2023, with projections indicating continued growth through 2034. The United States contributed the largest share, with approximately 47% of the diagnosed prevalent population, while Germany and Japan each accounted for roughly 10% of the total 7MM patient pool. When examining disease severity, approximately 521K mild cases and 860K moderate to severe cases were identified across these markets.

 

Discover evolving trends in Ulcerative Colitis patient pool forecasts @ Ulcerative Colitis Epidemiology Analysis

 

The ulcerative colitis treatment market currently encompasses multiple therapeutic approaches, including aminosalicylates, corticosteroids, immunomodulators, biologic therapies, S1P modulators, and Janus kinase inhibitors. Anti-TNF alpha agents remain the recommended first-line treatment option for many patients. Among the currently approved therapies, HUMIRA (AbbVie), REMICADE (Janssen Pharmaceuticals), SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda Pharmaceuticals), XELJANZ (Pfizer), STELARA (Janssen Pharmaceuticals), CAROGRA (EA Pharma/Kissei Pharma), JYSELECA (Gilead Sciences and Galapagos NV), OMVOH (Eli Lilly), SKYRIZI (AbbVie/Boehringer Ingelheim), RINVOQ (AbbVie), and ZEPOSIA (Bristol-Myers Squibb), among others have established strong market positions. By 2034, ENTYVIO is projected to generate the highest revenue in the United States, followed by HUMIRA (AbbVie).

 

In December 2024, Biocon Biologics and Celltrion received FDA approval for their respective biosimilars to STELARA (Janssen Pharmaceuticals) – YESINTEK (Biocon Biologics) and STEQEYMA (Celltrion) – expanding treatment options for patients with ulcerative colitis. In February 2024, the European Commission granted marketing authorization for VELSIPITY (etrasimod) for patients 16 years and older with moderately to severely active ulcerative colitis following its FDA approval in October 2023.

 

The ulcerative colitis therapeutics market is witnessing significant innovation with several emerging therapies such as, Etrasimod (Arena Pharmaceuticals/Pfizer), ABX464 (Abivax), SHR0302 (Reistone Biopharma), Cobitolimod (InDex Pharmaceuticals), TREMFYA (Janssen Pharmaceuticals), BT-11 (Landos Biopharma/NImmune), PRA023 (Merck), Remestemcel-L (Mesoblast), PF-06651600 (Pfizer) and PF-06700841 (Pfizer) among others.

 

Know which Ulcerative Colitis drug is expected to capture the largest market share in 7MM by 2034. Visit the Ulcerative Colitis Insights

 

Recent developments have further enriched the ulcerative colitis market with several regulatory approvals and clinical advancements. In December 2024, Accropeutics Inc. announced FDA clearance for a Phase II trial of its RIPK2 inhibitor, AC-101, for moderate-to-severe Ulcerative Colitis. Additionally, in November 2024, Johnson & Johnson submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of TREMFYA (guselkumab). In late 2024, AbbVie’s SKYRIZI had rapidly outpaced Eli Lilly’s OMVOH in the ulcerative colitis market, securing over double the market share just two months post-launch.

 

In January 2025, the FDA granted investigational new drug (IND) clearance for R-5780 (Rise Therapeutics). This innovative therapy leverages gut-regulated immune pathways to enhance the efficacy of immune checkpoint inhibitors, offering a novel approach to treating cancers that are refractory or unresponsive to these therapies.

 

Looking ahead, the ulcerative colitis market is expected to witness significant transformation with the introduction of novel therapeutic classes, including toll-like receptor 9 activators, miR-124 enhancers, and T-cell therapies. While high therapy costs and complications pose challenges, rising awareness, early screening, and advanced treatment strategies are fueling ulcerative colitis treatment market growth.

 

The ulcerative colitis epidemiology and the market landscape present both opportunities and challenges for stakeholders. As treatment paradigms continue to evolve, focusing on personalized medicine and improved patient outcomes, the ulcerative colitis treatment market is positioned for substantial growth, offering new hope for the millions affected by this chronic inflammatory condition worldwide.

 

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

Ulcerative Colitis Market Overview at a Glance

4.

Epidemiology and Market Methodology

5.

Ulcerative Colitis Executive Summary

6.

Ulcerative Colitis Market Disease Background and Overview

7.

Ulcerative Colitis Epidemiology and Patient Population

8.

Patient Journey

9.

Ulcerative Colitis Marketed Therapies

10.

Ulcerative Colitis Emerging Drugs

11.

Ulcerative Colitis: The 7MM Analysis

12.

Ulcerative Colitis Market Access and Reimbursement

13.

Ulcerative Colitis KOL Views

14.

Ulcerative Colitis SWOT Analysis

15.

Ulcerative Colitis Unmet Needs

16.

Appendix

17.

DelveInsight Capabilities

18.

Disclaimer

 

Related Reports

Ulcerative Colitis Pipeline Insight

Ulcerative Colitis Pipeline Insight provides comprehensive insights about the Ulcerative Colitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Ulcerative Colitis manufacturers, including Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, and Palatin Technologies, among others.

 

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Market Set for Robust Growth Across the 7MM from USD 8.4 Billion in 2023 | DelveInsight

Influenza A Infections Market Across the 7MM Expected to Experience Significant Growth by 2032 | DelveInsight

Key Influenza A Infections companies in the market include – Roche, GSK, BioCryst Pharmaceuticals, Genentech, Shionogi & Co., Sanofi, Cidara Therapeutics, SAb Biotherapeutics, Vir Biotechnology, and Micron Biomedical, among others.

 

The influenza A infections market is expected to grow significantly across the 7MM, which includes the United States, EU4—Germany, France, Italy, and Spain—the United Kingdom, and Japan. This growth can be attributed to several factors, including increasing vaccination rates, innovative antiviral therapies, and government-backed initiatives aimed at combating seasonal influenza. Key players driving innovation in this field include Roche, GSK, BioCryst Pharmaceuticals, Genentech, Shionogi & Co., Sanofi, Cidara Therapeutics, SAb Biotherapeutics, Vir Biotechnology, and Micron Biomedical, among others.

 

DelveInsight’s report titled “Influenza A Infections – Market Insight, Epidemiology And Market Forecast – 2032” provides a comprehensive analysis of the historical and projected market size for Influenza A infections from 2019 to 2032. The report examines various epidemiological segments and forecasts, explores market trends for Influenza A infections, assesses the competitive landscape, evaluates current and emerging therapeutic approaches, and identifies unmet needs in the treatment of Influenza A infections.

 

According to the report, the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, reached USD 3.6 billion in 2021. The market is expanding steadily due to rising vaccination rates, innovative antiviral therapies, and government-backed initiatives aimed at combating seasonal influenza. Projections indicate sustained growth through 2032, with the U.S. dominating the market among the 7MM countries.

 

Download the influenza A market report to understand which factors are driving the influenza A therapeutic market @ Influenza A Market Trends

 

The epidemiological data presented in the report highlights the significant impact of Influenza A across the 7MM, with patterns emerging in prevalence, strain distribution, and vaccination rates. One of the most notable trends is the increasing prevalence of Influenza A infections. In the US alone, over 176 million individuals were vaccinated against Influenza A in 2021. More recently, Influenza A strains, primarily A/H3N2 and A/H1N1 which tend to be more severe due to their higher transmissibility and virulence, are attributed to most of the recent cases, especially in 2024-2025. This underscores the widespread nature of the virus, especially among seasonal strains.

 

Discover evolving trends in influenza A patient pool forecasts @ Influenza A Epidemiology Analysis

 

The Influenza A treatment landscape comprises established antiviral medications, emerging therapies, and preventive strategies that aim to mitigate the disease’s impact. Current therapeutics focus on reducing the severity and duration of symptoms, preventing complications, and addressing challenges posed by evolving viral strains. Recommended antiviral drugs for treatment include TAMIFLU (Roche), RELENZA (GSK), RAPIVAB (BioCryst Pharmaceuticals), XOFLUZA (Genentech/Roche/Shionogi & Co.), and FLUZONE QUADRIVALENT (Sanofi), among others. These antiviral medications shorten the duration of symptoms and reduce the risk of severe complications in high-risk populations.

 

DelveInsight’s analysis indicates that the current developmental pipeline for influenza treatments is robust. Notable candidates include CD388 (Cidara Therapeutics), SAB-176 (SAB Biotherapeutics), and VIR-2482 (Vir Biotechnology), among others. These therapies represent significant advancements in addressing unmet needs in Influenza A prevention and treatment, particularly for high-risk populations and those facing vaccine limitations.

 

Recent developments in the Influenza A landscape across the 7MM highlight significant advancements in vaccine technology, antiviral therapies, and emerging drug candidates, reshaping the prevention and treatment of Influenza A and addressing both seasonal epidemics and pandemic preparedness. An important advancement in the influenza landscape is the shift towards mRNA-based vaccine technologies. Following the success of mRNA vaccines for COVID-19, pharmaceutical companies are strategically repurposing this technology for influenza vaccines.

 

Another significant change is the transition from egg-based production methods to cell culture-based methods. This shift offers enhanced flexibility, scalability, and safety in production. Cell culture-based methods help meet vaccine demands more sustainably and ensure timely supply during both seasonal epidemics and potential global pandemics.

 

The quest for a universal influenza vaccine, which could provide broad and durable protection against all influenza virus strains, continues to be a priority. Current strategies focus on targeting highly conserved regions of hemagglutinin (HA), neuraminidase (NA), the M2 extracellular domain (M2e), and internal proteins of the influenza virus.

 

Innovation in vaccine delivery systems is also progressing rapidly. In January 2025, Micron Biomedical received a $2 million award from the U.S. Department of Health and Human Services to develop needle-free versions of broadly protecting influenza vaccines in collaboration with Zipcode Bio. In September 2024, the FDA also approved FluMist for the prevention of influenza caused by influenza virus subtypes A and B in individuals 2 through 49 years of age.

 

Unlock which influenza A drug is expected to capture the largest market share in 7MM by 2034. Visit the Influenza A Insights

 

Additionally, the FDA has recommended updated formulations for the 2025–2026 influenza vaccine, which include new strains of Influenza A/H3N2 viruses to improve efficacy against circulating variants.

 

Looking ahead, the Influenza A infections market looks promising with advancements in treatment and prevention strategies aimed at overcoming resistance challenges and improving outcomes for high-risk populations. Strategic partnerships among leading pharmaceutical companies will accelerate research and development efforts, while government-backed initiatives will continue to enhance vaccination rates.

 

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

Executive Summary

4.

Key Events

5.

SWOT Analysis

6.

Influenza A Epidemiology and Market Forecast Methodology

7.

Influenza A Market Overview at a Glance in the 7MM

8.

Disease Background and Overview

9.

Influenza A Treatment and Guidelines

10.

Guidelines

11.

Influenza A Epidemiology and Patient Population in the 7MM

12.

Influenza A Patient Journey

13.

Key Endpoints in Influenza A

14.

Influenza A Marketed Vaccines and Drugs

15.

Influenza A Emerging Vaccines and Drugs

16.

Influenza A: 7MM Market Analysis

17.

Influenza A Unmet Needs

18.

Market Access and Reimbursement

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

 

Related Reports

Influenza A Infections Pipeline Insight

Influenza A Infections Pipeline Insight provides comprehensive insights about the Influenza A Infections pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Influenza A Infections manufacturers, including Roche, GSK, BioCryst Pharmaceuticals, Genentech, Shionogi & Co., Sanofi, Cidara Therapeutics, SAb Biotherapeutics, Vir Biotechnology, and Micron Biomedical, among others.

 

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Influenza A Infections Market Across the 7MM Expected to Experience Significant Growth by 2032 | DelveInsight

Golden Years Home Care Enhances Elder Care with Compassionate Companion Care in San Diego

Meeting the growing demand for senior companionship in Coronado and beyond

Coronado, CA – Golden Years Home Care proudly announces its steadfast dedication to improving the quality of life for seniors and their families by offering exceptional companion care in San Diego. Focusing Home Care continues to respond to the community’s need for reliable and empathetic elder care services, focusing on compassionate and personalized assistance.

“At Golden Years Home Care, we believe that every senior deserves dignity, comfort, and companionship,” said Ken Ballard, the owner of Golden Years Home Care. “Our team is committed to addressing the unique needs of each individual, ensuring seniors across San Diego have access to the care they need to thrive. With our companion care services, families can rest assured their loved ones are supported every step of the way.”

Elder care in San Diego remains a critical focus area as an aging population highlights the importance of comprehensive care solutions. Golden Years Home Care specializes in tailoring services to help seniors maintain independence, providing support ranging from companionship to assistance with daily tasks. These efforts ensure a higher quality of life while alleviating the caregiving burden on families.

Companion care transforms seniors’ daily lives by creating meaningful connections that reduce loneliness and foster emotional well-being. Regular companionship can brighten a senior’s day, offering them someone to share stories with, enjoy activities alongside, or simply be present to listen and engage. These connections build a sense of belonging and can significantly boost mental and emotional health.

Beyond emotional support, companion care promotes physical activity and healthy routines. Whether accompanying seniors on daily walks, assisting with meal preparation, or encouraging them to pursue hobbies, caregivers ensure that seniors remain active and maintain a fulfilling lifestyle. This support often leads to increased energy, improved health, and an enhanced sense of purpose.

Families seeking top-tier companion care in San Diego can trust Golden Years Home Care for reliable and professional support. To learn more about their companion care in San Diego, CA, please visit their website at https://goldenyearshomecare.com/san-diego-ca.

About Golden Years Home Care:

Golden Years Home Care is a leading provider of elder care services in San Diego. It offers compassionate, personalized assistance tailored to seniors’ needs, from companionship to daily support. Golden Years Home Care is dedicated to enriching seniors’ lives while fostering peace of mind for their families. The company’s mission is to ensure that every senior receives the respect and care they deserve.

Media Contact
Company Name: Golden Years Home Care (San Diego, CA)
Email: Send Email
Phone: (916) 333-0383
Address:301 SPRUCE ST, STE 101
City: San Diego
State: California 92103-5626
Country: United States
Website: https://goldenyearshomecare.com/san-diego-ca/

EULA Home Care Agency Expands Respite Care Services to Families in Harrisburg, NC

Offering peace of mind and essential support for family caregivers through in-home care

Harrisburg, NC – EULA Home Care Agency, under the leadership of Davetta Williams, proudly continues its mission to provide dedicated respite care and in-home care services to families throughout Harrisburg, NC. As demand for high-quality, compassionate care rises, EULA Home Care Agency’s expansion into respite care services aims to provide family caregivers a much-needed break while ensuring their loved ones receive attentive, professional care at home.

“At EULA Home Care Agency, we understand that caring for a loved one is a deeply personal and challenging commitment. Our respite care services are designed to give family members a chance to rest and recharge while knowing their loved ones are in trusted hands,” said Davetta Williams, owner of EULA Home Care Agency. “Our team is devoted to delivering top-tier care, compassion, and peace of mind to families across Harrisburg.”

With a focus on Harrisburg’s aging community, EULA Home Care Agency’s respite care solutions address the growing need for reliable support tailored to individual needs. Services include help with daily activities, companionship, and personalized care plans crafted by experienced caregivers to enhance comfort and well-being.

Many family members caring for an aging loved one experience emotional, physical, and mental strain, balancing personal responsibilities alongside caregiving. Respite care offers an essential reprieve from these challenges, allowing caregivers to temporarily step back, rest, and regain the energy needed to provide the best care for their loved ones. By providing supportive services, EULA Home Care Agency ensures families can access quality, dependable care at critical times.

Respite care also serves as a preventative measure against burnout. Studies show that caregivers who neglect self-care may face increased risks of stress-related health issues, including depression and anxiety. Regular breaks through respite care help alleviate these risks, allowing family caregivers to preserve their well-being while fostering a stronger, more positive relationship with their loved ones. With a team of skilled caregivers trained to handle basic and advanced care needs, the EULA Home Care Agency provides a reliable solution for families seeking trusted support.

Beyond providing short-term relief, respite care can also help families explore ongoing care options if needed. Many caregivers find that professional support can be an invaluable part of a loved one’s long-term care plan, as it brings peace of mind knowing qualified caregivers are available. EULA Home Care Agency offers flexible respite care plans tailored to individual needs, allowing families to choose options that align best with their unique situations. By prioritizing professional, compassionate care, EULA Home Care Agency empowers families to manage the caregiving journey confidently.

For more information on EULA Home Care Agency and their respite care in Harrisburg, visit their website at https://eulahomecare.com.

About EULA Home Care Agency:

EULA Home Care Agency is a dedicated provider of compassionate and professional in-home care services. Known for its commitment to improving the lives of seniors and families, the agency offers a range of services, including respite care, to meet each client’s unique needs. With a team of skilled caregivers, EULA Home Care Agency empowers families in Harrisburg to maintain their quality of life with dignity and comfort in their homes.

Media Contact
Company Name: EULA Home Care Agency
Contact Person: Davetta Williams
Email: Send Email
Phone: +1 704 549 8300
Address:8430 University Executive Park Dr Suite 606
City: Charlotte
State: NC
Country: United States
Website: http://www.eulahomecare.com

All Dry Services Named One of the Best Franchise Opportunities Under $150,000 in Entrepreneur Magazine

Tequesta, FL – April 11, 2025 – All Dry Services, a rapidly growing leader in water damage restoration and mold remediation, has been recognized as one of the best franchise investments under $150,000. With low startup costs, a recession-resistant business model, and booming demand across the U.S., All Dry is paving the way for entrepreneurs seeking a high-growth opportunity in the essential services sector.

Founded in 2014 and franchising since 2020, All Dry Services has quickly built a reputation for exceptional customer service, fast response times, and an unwavering commitment to restoring properties and peace of mind. With a total investment starting under $150,000, the franchise offers a compelling opportunity with strong profit potential and nationwide support.

“We’re proud to offer a franchise opportunity that’s not only affordable but also meaningful,” said Matt Kuntz, Founder and Chairman of All Dry Services. “We help people during some of their most stressful times, and our franchisees are making a real difference in their communities every day.”

Why Entrepreneurs Are Choosing All Dry:

  • Low Investment: Total startup costs under $150,000, including franchise fee, equipment, and initial marketing.
  • Essential Industry: Restoration services are always in demand—regardless of the economy.
  • Scalable Business: Franchisees can start with one vehicle and grow into multiple territories.
  • Ongoing Support: From marketing and lead generation to 24/7 operational support, All Dry offers unmatched resources for franchisee success.
  • Quick Start-Up: Get your business up and running in as little as 30–60 days.

With hundreds of territories available nationwide, All Dry is inviting driven individuals to join a fast-growing brand with a mission to help people recover from property damage with care, speed, and expertise.

About All Dry Services:

All Dry Services specializes in water and storm damage restoration, mold remediation, odor removal, and more. Headquartered in Tequesta, FL, All Dry is a trusted name in property restoration and has received multiple accolades for innovation and franchisee satisfaction.

Media Contact
Company Name: All Dry Services
Contact Person: Jason Molzer
Email: Send Email
Phone: 561-906-8049
Address:582 N Us Hwy 1
City: Jupiter
State: FL
Country: United States
Website: www.myalldry.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: All Dry Services Named One of the Best Franchise Opportunities Under $150,000 in Entrepreneur Magazine

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031—a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology’s toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades.

Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology—using naturally occurring canine cancers as research models—are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that’s evolving faster than ever before.

Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let’s take a closer look at how some of the most innovative players in this space are tackling these pressing challenges.

OS Therapies (NYSE-A: OSTX) is focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company’s lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein.

Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients.

This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease.

The combination of these results marks a critical milestone in OS Therapies’ development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026.

The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects.

As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans.

Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term.

The company’s growth isn’t limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology.

As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer.

Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer.

OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption—more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone.

In late 2024, OJEMDA also earned the “Exclusively Pediatric” designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One’s pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026.

Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA.

From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million—largely due to R&D and launch costs—the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts.

Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer.

GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK’s experimental antibody-drug conjugates (ADCs) that targets B7-H3—a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who’ve already gone through two lines of treatment. That’s a big deal in a space with no currently approved therapies for patients at that stage.

Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK’s drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly.

On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK’s pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year—including a relaunch of its blood cancer drug Blenrep—the company looks well-positioned to keep growing in high-need treatment areas.

ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine).

Recent clinical trial results further solidify the company’s growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company’s profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear.

Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication.

From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

Leads Technologies Limited Expands Presence and Product Offerings in Asia’s Digital Transformation Sector

Established in 2015, Leads Technologies Limited (Leadstec) has steadily expanded its operations across Asia, offering enterprise-level digital solutions focused on content management, customer experience, analytics, and automation. Headquartered in Hong Kong with additional offices in Guangzhou and Taiwan, the company has developed both proprietary technologies and integrated third-party platforms to support enterprise digital transformation projects.

Company Development and Milestones

Since its founding, Leads Technologies has built its capabilities in digital content and experience management, beginning with the formation of an Adobe-focused implementation team in 2016. In 2017, it achieved Adobe Bronze Solution Partner status. By 2020, it had been certified as a Specialized Adobe Experience Manager Partner, a designation granted to companies with demonstrated technical proficiency and successful deployment histories.

To support regional growth, the company established a design-focused UX/UI team in 2018 and launched its internally developed enterprise resource planning (ERP) platform in 2019. In 2023, it released “AI Secretary,” a no-code chatbot solution built to integrate with platforms such as WhatsApp, Line, and WeChat. Its Taiwan office opened in 2024 to serve increasing demand across Greater China.

Products and Technologies

Leads Technologies provides enterprise services through both proprietary and partner technologies. These include Adobe Experience Manager, Adobe Analytics, Adobe Target, and Adobe Commerce, among others, alongside Magnolia CMS and Google Analytics. The company’s own platforms—such as AI Secretary and Leadstec ERP—are designed to support customer interaction, content automation, and business process management.

It also developed a custom Adobe Campaign connector for WeChat, extending Adobe’s cross-channel campaign management to one of China’s leading messaging platforms.

Key Services

The company’s service offerings include:

  • UX/UI design and frontend development

  • SEO/SEM optimization and web analytics

  • Content strategy, translation, and localization

  • Enterprise application development using Java

  • Marketing automation and personalization

  • Performance testing and website optimization

These services are delivered to support large-scale implementations across sectors such as finance, telecommunications, tourism, and education.

Client Projects

Leads Technologies has supported several regional and multinational clients. Notable projects include:

  • Hong Kong Tourism Board: Development of a multilingual tourism platform using Adobe Experience Manager, integrated with SSO and third-party systems for content and analytics.

  • China CITIC Bank International: Digital form implementation to support paperless services via AEM Forms.

  • TVB: Viewer data segmentation using Adobe Audience Manager and Adobe Analytics.

  • Hong Kong Baptist University: Website redesign using AEM as a Cloud Service, adding content governance and multilingual support.

  • Huawei Consumer Business Group: Deployment of over 90 regional websites and centralized digital asset management.

  • OnePlus: Regional site rollout with modular content and localization using AEM.

  • Construction Industry Council: Platform unification and multilingual features using AEM Cloud Service.


Partnerships and Certifications

Leads Technologies is recognized as a certified partner of both Adobe and Magnolia. Its partnership with Adobe includes specialization in Adobe Experience Manager, reflecting its consistent delivery of projects across Asia-Pacific markets. It is also a certified implementation partner of Magnolia CMS.

Future Outlook

With its continued investment in AI-based solutions and regional expansion, Leads Technologies is positioning itself to address growing demands for enterprise digital transformation across Asia.

Media Contact
Company Name: Leads Technologies Limited
Contact Person: Sales
Email: Send Email
City: Hong Kong
Country: China
Website: www.leads-technologies.com/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leads Technologies Limited Expands Presence and Product Offerings in Asia’s Digital Transformation Sector

Prime Heating & Cooling LLC Expands Services to Meet Growing Demand in Franklin

Prime Heating & Cooling LLC Expands Services to Meet Growing Demand in Franklin
Prime Heating & Cooling LLC is expanding its services to meet the increasing demand for reliable heating and cooling solutions in Franklin and surrounding areas. With a reputation for quality workmanship and exceptional customer service, the company is enhancing its offerings to ensure homeowners and businesses receive top-tier HVAC solutions.

As a leading HVAC Contractor Franklin, Prime Heating & Cooling LLC provides expert installation, maintenance, and repair services for residential and commercial properties. The company’s skilled technicians specialize in optimizing heating and cooling systems for maximum efficiency, helping clients maintain comfortable indoor environments year-round. By offering customized solutions tailored to each property’s needs, the company ensures long-term performance and reliability.

In response to growing interest in energy-efficient solutions, the company has strengthened its focus on Heat Pump Installation Franklin. Heat pumps have become preferred for homeowners seeking cost-effective and environmentally friendly alternatives to traditional heating and cooling systems. Prime Heating & Cooling LLC offers professional installation services, ensuring customers benefit from lower energy costs and enhanced indoor comfort. The company also provides expert guidance on selecting the best heat pump models to maximize energy savings and performance.

Recognizing the urgency of unexpected breakdowns, Prime Heating & Cooling LLC has expanded its Emergency AC Repair Franklin services. With technicians available around the clock, the company prioritizes fast response times to restore cooling systems when they are needed most. Whether addressing sudden malfunctions or performing critical repairs, the team is committed to providing prompt and effective solutions. Emergency repair services extend to all major AC brands, ensuring customers receive high-quality service regardless of their system type.

Prime Heating & Cooling LLC remains dedicated to serving the Franklin community with high-quality heating and cooling services. The company’s latest service expansions reinforce its commitment to customer satisfaction, energy efficiency, and reliable climate control solutions.

For more information about Prime Heating & Cooling LLC and its services, visit https://getprimehvac.com/franklin-ma/ or call (508) 466-5564.

Media Contact
Company Name: Prime Heating & Cooling LLC
Contact Person: Tyler Steiner
Email: Send Email
Phone: (508) 466-5564
Address:55 W Central St Unit 1
City: Franklin
State: MA 02038
Country: United States
Website: https://getprimehvac.com/franklin-ma/

Leadstec Drives Innovation with Enterprise-Grade Digital Solutions

Leads Technologies Limited (Leadstec), a leading digital transformation solutions provider headquartered in Hong Kong, continues to set benchmarks in the enterprise technology sector with its expanding suite of enterprise-grade digital solutions. Through strategic innovation, strong global partnerships, and proprietary platform development, Leadstec is driving measurable impact for organizations seeking scalable digital transformation.

Founded in 2015, Leadstec has rapidly evolved into a key player in the Asia-Pacific region’s digital ecosystem. The company offers end-to-end services encompassing content management systems (CMS), enterprise resource planning (ERP), data analytics, AI automation, user experience (UX/UI) design, and performance optimization. Its robust solutions are tailored to meet the demands of large-scale enterprises while also catering to small and medium-sized businesses (SMEs) undergoing digital modernisation.

Leadstec holds the distinction of being the only local Chinese partner in Greater China recognized as a Specialized Adobe Experience Manager Partner. In addition, it maintains official partnerships with Magnolia CMS and HCL, further reinforcing its commitment to delivering best-in-class digital infrastructure solutions to clients.

“Our mission has always been to empower enterprises through cutting-edge technology that’s both powerful and practical,” said a Leadstec spokesperson. “By integrating proprietary platforms with global software tools, we’re able to accelerate our clients’ transformation journeys with reliability and speed.”

Among Leadstec’s proprietary innovations is AI Secretary, a no-code, AI-powered chatbot platform that utilizes state-of-the-art large language models (LLMs) such as GPT-4. Designed for ease of use and scalability, AI Secretary enables organizations to automate customer and internal communications, integrating seamlessly with platforms like WeChat, WhatsApp, and Line. It supports custom branding, document-based training, and real-time analytics to help enterprises optimize interaction performance.

Another flagship solution, Leadstec ERP, is a modular enterprise resource planning system developed in-house to help businesses manage operations, workflows, and data integrations. The ERP system has been deployed successfully across industries including finance, manufacturing, and higher education.

Noteworthy project implementations include:

  • A multilingual tourism platform for the Hong Kong Tourism Board, integrating Single Sign-On, coupons, and analytics.

  • AEM Forms digital workflows for China CITIC Bank International, enhancing customer onboarding and compliance.

  • Adobe Audience Manager and Analytics tools deployed for TVB to fine-tune programming strategies based on audience behaviour.

  • Website modernization and asset management systems delivered to clients such as Huawei, OnePlus, AIA, and Hong Kong Baptist University.

Leadstec has also played a pivotal role in assisting SMEs with digital transformation, providing turnkey solutions in e-commerce, CRM, mobile app development, and process automation, contributing to improved operational efficiency and market agility.

With offices in Hong Kong, Guangzhou, and a new branch in Taiwan, Leadstec continues to expand its regional footprint and technological portfolio. As digital ecosystems become increasingly complex, the company is investing in AI, cloud-native platforms, and integration services to meet the rising expectations of modern enterprises.

About Leads Technologies Limited

Founded in 2015, Leads Technologies Limited (Leadstec) is a Hong Kong-based technology company specializing in enterprise digital solutions. The company provides services across content management, analytics, UX/UI, ERP, and AI platforms. Leadstec is an official partner of Adobe, Magnolia, and HCL, and the only Chinese company recognized as a Specialized Adobe Experience Manager Partner in the Greater China region. Clients include Huawei, Samsung, OPPO, Nissan, Dah Sing Bank, and the Hong Kong Tourism Board.

Media Contact
Company Name: Leads Technologies Limited
Contact Person: Sales
Email: Send Email
City:
Country: Taiwan
Website: www.leads-technologies.com/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leadstec Drives Innovation with Enterprise-Grade Digital Solutions